Novartis strikes $7.8 billion mRNA deal with China's Abogen
Swiss drug maker Novartis has signed a licensing and option agreement with Chinese biotech firm Abogen worth approximately $7.8 billion to advance RNA-based therapy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.